Tirzepatide Mechanism of Action (MOA)

Here is a detailed breakdown of its mechanism of action:

Tirzepatide is a synthetic peptide that primarily mimics the action of GIP but is engineered to activate both the GIP and GLP-1 receptors effectively . This dual activation works synergistically to regulate metabolism through several key pathways:

Target Tissue/System Primary Mechanism of Action Physiological Outcome
Pancreas (β-cells) Enhances glucose-dependent insulin secretion . Lowers blood glucose levels only when they are high, with low risk of hypoglycemia.
Pancreas (α-cells) Suppresses glucagon secretion in a glucose-dependent manner . Reduces endogenous glucose production by the liver.
Brain (Appetite Centers) Activates neurons in regions regulating appetite and food intake . Decreases appetite, increases satiety, and reduces food cravings, leading to lower calorie intake.
Stomach Delays gastric emptying . Slows the absorption of nutrients, reducing post-meal blood sugar spikes.
Adipose Tissue (Fat Cells) Acts on GIP receptors to modulate lipid uptake and lipolysis; promotes fat utilization . Contributes to a greater reduction in body fat mass compared to fat-free mass.

The way tirzepatide interacts with its target receptors is not identical to that of natural hormones, which contributes to its high efficacy:

· GIP Receptor (GIPR) Dominance: Tirzepatide has a higher affinity for the GIP receptor and activates it in a way that closely mimics the natural GIP hormone . This strong GIPR engagement is thought to enhance insulin sensitivity and fat metabolism.
· GLP-1 Receptor (GLP-1R) Bias: At the GLP-1 receptor, tirzepatide acts differently from natural GLP-1. It shows "bias" by strongly stimulating the pathway that produces cAMP (a molecule that promotes insulin secretion) while having a weaker effect on recruiting β-arrestin, a protein that can lead to receptor desensitization and internalization . This may result in more sustained signaling from the GLP-1 receptor.
· Long-Acting Design: A C20 fatty diacid moiety is attached to the peptide, which allows it to bind tightly to albumin in the blood . This slows its breakdown and clearance from the body, giving it a long half-life of about 5 days and enabling once-weekly dosing .